Replimune Group Future Growth
Future criteria checks 2/6
Replimune Group is forecast to grow earnings and revenue by 26% and 57.8% per annum respectively while EPS is expected to grow by 31.9% per annum.
Key information
26.0%
Earnings growth rate
31.9%
EPS growth rate
Biotechs earnings growth | 30.0% |
Revenue growth rate | 57.8% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 13 Aug 2024 |
Recent future growth updates
Recent updates
Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?
Aug 16Replimune: Continuing To Justify The Bear Thesis (For Now)
May 22Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 110 | -145 | -186 | N/A | 3 |
3/31/2026 | 15 | -217 | -200 | N/A | 4 |
3/31/2025 | 3 | -219 | -181 | -177 | 7 |
6/30/2024 | N/A | -220 | -193 | -186 | N/A |
3/31/2024 | N/A | -216 | -191 | -185 | N/A |
12/31/2023 | N/A | -210 | -176 | -172 | N/A |
9/30/2023 | N/A | -199 | -157 | -154 | N/A |
6/30/2023 | N/A | -182 | -145 | -143 | N/A |
3/31/2023 | N/A | -174 | -130 | -128 | N/A |
12/31/2022 | N/A | -157 | -121 | -118 | N/A |
9/30/2022 | N/A | -147 | -111 | -108 | N/A |
6/30/2022 | N/A | -133 | -100 | -97 | N/A |
3/31/2022 | N/A | -118 | -85 | -82 | N/A |
12/31/2021 | N/A | -108 | -78 | -76 | N/A |
9/30/2021 | N/A | -100 | -72 | -70 | N/A |
6/30/2021 | N/A | -91 | -66 | -65 | N/A |
3/31/2021 | N/A | -81 | -64 | -61 | N/A |
12/31/2020 | N/A | -75 | -59 | -57 | N/A |
9/30/2020 | N/A | -70 | -66 | -59 | N/A |
6/30/2020 | N/A | -61 | -69 | -62 | N/A |
3/31/2020 | N/A | -53 | -67 | -61 | N/A |
12/31/2019 | N/A | -43 | -62 | -55 | N/A |
9/30/2019 | N/A | -35 | -49 | -46 | N/A |
6/30/2019 | N/A | -30 | -35 | -32 | N/A |
3/31/2019 | N/A | -31 | -28 | -25 | N/A |
12/31/2018 | N/A | -31 | -24 | -24 | N/A |
9/30/2018 | N/A | -28 | -20 | -20 | N/A |
6/30/2018 | N/A | -26 | -18 | -17 | N/A |
3/31/2018 | N/A | -20 | N/A | -16 | N/A |
12/31/2017 | N/A | -17 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: REPL's revenue (57.8% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: REPL's revenue (57.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if REPL's Return on Equity is forecast to be high in 3 years time